J. Melville Engle's most recent trade in Predictive Oncology Inc was a trade of 213,300 Common Stock done . Disclosure was reported to the exchange on Nov. 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Predictive Oncology Inc | J. Melville Engle | FORMER CEO AND FORMER DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 213,300 | 416,693 (10%) | 5% | 0 | Common Stock | |
| Predictive Oncology Inc | J. Melville Engle | Director | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 24 May 2022 | 159,500 | 203,393 (5%) | 3% | 0.4 | 59,334 | Common Stock |
| Predictive Oncology Inc | J. Melville Engle | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 20,428 | 43,893 (1%) | 0% | 0 | Common Stock | |
| Predictive Oncology Inc | J. Melville Engle | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 4,512 | 23,465 (0%) | 0% | 0 | Common Stock | |
| Predictive Oncology Inc | J. Melville Engle | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 9,924 | 18,953 (0%) | 0% | 0 | Common Stock | |
| Predictive Oncology Inc | J. Melville Engle | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 4,959 | 9,029 (0%) | 0% | 0 | Common Stock | |
| Predictive Oncology Inc | J. Melville Engle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 6,142 | 6,142 | - | - | Stock Options (right to buy) |